The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
_256_384.jpg)
In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report
The acquisition complements Gilead’s existing oncology expertise and development infrastructure
The acquisition aims to bolster Merck’s hematology portfolio with Terns’ lead oncology candidate, TERN-701
The drug meets all primary endpoints across 608 patients in Europe and India, strengthening the company's biosimilars pipeline
The company has highlighted setbacks in Phase II studies while outlining fresh regulatory and late-stage development plans for Fibromun and Nidlegy
As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
The initial consideration for the transaction is US$ 12 million
Achondroplasia, a rare genetic disorder, causes skeletal dysplasia and often increases the risk of muscular, neurological, and cardiorespiratory complications
Subscribe To Our Newsletter & Stay Updated
